Mdicaments psychothrapies estce les seuls choix possibles Dr

« Médicaments, psychothérapies, est-ce les seuls choix possibles ? » Dr Philippe Henaux Journée de l’ASMA (Association scientifique de médecine d’Assurance) 22 novembre 2018 Salle Dupréel Institut de Sociologie ULB

La Libre Belgique, 8 octobre 2002

« Médicaments, psychothérapies, est-ce les seuls choix possibles ? » Dr Pierre Cole Journée de l’ASMA (Association scientifique de médecine d’Assurance) 22 novembre 2018 Salle Dupréel Institut de Sociologie ULB

Potential conflict of interest Missions de consultances pour Janssens®

Potential conflict of interest Missions de consultances pour Janssens® Responsable académique du certificat universitaires en thérapie cognitivocomportementale à l’Université libre de Bruxelles Attentio n !!!

Le premier devoir d'une société est de reconnaître qu'il n'existe pas une seule réponse à la souffrance psychique", laquelle n'est "ni évaluable ni mesurable « Philippe Douste-Blazy 8 février 2005

• Data come from National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III) 2012 -2013 • 36309 adults • 12 -month and life time prevalences of DSM-5 MDD were 10. 4% and 20. 6% respectively Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018 Apr 1; 75(4): 336346.

Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018 Apr 1; 75(4): 336 -346.

• Data come from the World Health Organization (WHO) WMH surveys, a series of 23 community epidemiological surveys administered in 21 countries. • 4. 6% of respondents met 12 -month criteria for DSM-IV/CIDI MDD • 56. 7% respondents with 12 -month MDD across surveys reported that they recognised that they needed treatment • 71. 1% made at least one visit to some service provider for their emotional problems (including visits to religious advisors or traditional healers) • Among patients who received treatment, 41. 0% met criteria for minimally adequate treatment (>1 month of a medication, plus >4 visits to any type of medical doctor) or psychotherapy (>8 visits with any professional including religious or spiritual advisor, social worker or counsellor). Thornicroft G, Chatterji S, Evans-Lacko S, Gruber M, Sampson N, Aguilar-Gaxiola S, et al. . Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry. 2017 Feb; 210(2): 119 -124.

New-York Times, 7 avril 2018

Zabegalov KN, Kolesnikova TO, Khatsko SL, Volgin AD, Yakovlev OA, Et al. Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. Eur J Pharmacol. 2018 Jun 15; 829: 129 -140.

Sequenced Treatment Alternatives to Relieve Depression (STAR-D) Sinyor M, Schaffer A, Levitt A (2010). "The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review". The Canadian Journal of Psychiatry. 55 (3): 126– 135.

5 -HT 2 B receptor acts as a direct positive modulator of serotonin Pet 1 -positive neurons in an opposite way as the known 5 -HT 1 Anegative autoreceptor.

Murphy JA, Sarris J, Byrne GJ. A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression. Depress Res Treat. 2017; 2017: 4176825.

Philip NS, Nelson BG, Frohlich F, Lim KO, Widge AS, Carpenter LL. Low-Intensity Transcranial Current Stimulation in Psychiatry. Am J Psychiatry. 2017 Jul 1; 174(7): 628639.

94 89 84 19 85 86 19 19 87 19 88 19 19 90 91 19 19 92 19 93 19 19 95 96 19 19 97 19 98 99 19 19 00 01 20 20 02 20 03 04 20 20 05 06 20 20 07 20 08 20 09 10 20 20 11 20 12 20 13 20 14 15 20 20 16 20 17 20 18 19 20 20 700 600 500 400 300 200 100 0

Müller VI, Cieslik EC, Serbanescu I, Laird AR, Fox PT, Eickhoff SB. Altered Brain Activity in Unipolar Depression Revisited: Meta-analyses of Neuroimaging Studies. JAMA Psychiatry. 2017 Jan 1; 74(1): 47 -55 .

Dr Pierre COLE CHU Brugmann pierre. cole@chu-brugmann. be